These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 23150683)

  • 21. Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma.
    Else T; Williams AR; Sabolch A; Jolly S; Miller BS; Hammer GD
    J Clin Endocrinol Metab; 2014 Feb; 99(2):455-61. PubMed ID: 24302750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Operative intervention for recurrence of adrenocortical carcinoma: A single-center experience.
    Zhang F; Liu Z; Liang J; Tang Y; Liu S; Zhou C; Zhang F; Wu K; Lu Y; Wang X
    Surgery; 2021 May; 169(5):1131-1138. PubMed ID: 33279225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of surgery in the management of recurrent adrenocortical carcinoma.
    Erdogan I; Deutschbein T; Jurowich C; Kroiss M; Ronchi C; Quinkler M; Waldmann J; Willenberg HS; Beuschlein F; Fottner C; Klose S; Heidemeier A; Brix D; Fenske W; Hahner S; Reibetanz J; Allolio B; Fassnacht M;
    J Clin Endocrinol Metab; 2013 Jan; 98(1):181-91. PubMed ID: 23150691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant Radiation is Associated with Improved Survival for Select Patients with Non-metastatic Adrenocortical Carcinoma.
    Nelson DW; Chang SC; Bandera BC; Fischer TD; Wollman R; Goldfarb M
    Ann Surg Oncol; 2018 Jul; 25(7):2060-2066. PubMed ID: 29748889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study.
    Weigand I; Altieri B; Lacombe AMF; Basile V; Kircher S; Landwehr LS; Schreiner J; Zerbini MCN; Ronchi CL; Megerle F; Berruti A; Canu L; Volante M; Paiva I; Della Casa S; Sbiera S; Fassnacht M; Fragoso MCBV; Terzolo M; Kroiss M
    J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32449514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?
    Kebebew E; Reiff E; Duh QY; Clark OH; McMillan A
    World J Surg; 2006 May; 30(5):872-8. PubMed ID: 16680602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center.
    Ayala-Ramirez M; Jasim S; Feng L; Ejaz S; Deniz F; Busaidy N; Waguespack SG; Naing A; Sircar K; Wood CG; Pagliaro L; Jimenez C; Vassilopoulou-Sellin R; Habra MA
    Eur J Endocrinol; 2013 Dec; 169(6):891-899. PubMed ID: 24086089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma.
    Reibetanz J; Jurowich C; Erdogan I; Nies C; Rayes N; Dralle H; Behrend M; Allolio B; Fassnacht M;
    Ann Surg; 2012 Feb; 255(2):363-9. PubMed ID: 22143204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adrenocortical carcinoma: Retrospective analysis of the last 22 years.
    Guelho D; Paiva I; Vieira A; Carrilho F
    Endocrinol Nutr; 2016 May; 63(5):212-9. PubMed ID: 26969077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of adrenocortical carcinoma in adrenal tumours greater than 8 cm.
    Abdel-Aziz TE; Rajeev P; Sadler G; Weaver A; Mihai R
    World J Surg; 2015 May; 39(5):1268-73. PubMed ID: 25526921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer.
    Berruti A; Fassnacht M; Haak H; Else T; Baudin E; Sperone P; Kroiss M; Kerkhofs T; Williams AR; Ardito A; Leboulleux S; Volante M; Deutschbein T; Feelders R; Ronchi C; Grisanti S; Gelderblom H; Porpiglia F; Papotti M; Hammer GD; Allolio B; Terzolo M
    Eur Urol; 2014 Apr; 65(4):832-8. PubMed ID: 24268504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stage Presentation, Care Patterns, Treatment Outcomes, and Impact of Radiotherapy on Overall Survival for Adrenocortical Carcinoma.
    Thomas JJ; Tward JD
    Clin Genitourin Cancer; 2021 Oct; 19(5):417-424. PubMed ID: 33858789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study.
    Terzolo M; Fassnacht M; Perotti P; Libé R; Kastelan D; Lacroix A; Arlt W; Haak HR; Loli P; Decoudier B; Lasolle H; Quinkler M; Haissaguerre M; Chabre O; Caron P; Stigliano A; Giordano R; Zatelli MC; Bancos I; Fragoso MCBV; Canu L; Luconi M; Puglisi S; Basile V; Reimondo G; Kroiss M; Megerle F; Hahner S; Kimpel O; Dusek T; Nölting S; Bourdeau I; Chortis V; Ettaieb MH; Cosentini D; Grisanti S; Baudin E; Berchialla P; Bovis F; Sormani MP; Bruzzi P; Beuschlein F; Bertherat J; Berruti A
    Lancet Diabetes Endocrinol; 2023 Oct; 11(10):720-730. PubMed ID: 37619579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane.
    Wängberg B; Khorram-Manesh A; Jansson S; Nilsson B; Nilsson O; Jakobsson CE; Lindstedt S; Odén A; Ahlman H
    Endocr Relat Cancer; 2010 Mar; 17(1):265-72. PubMed ID: 20026647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adrenocortical carcinoma: effect of hospital volume on patient outcome.
    Lombardi CP; Raffaelli M; Boniardi M; De Toma G; Marzano LA; Miccoli P; Minni F; Morino M; Pelizzo MR; Pietrabissa A; Renda A; Valeri A; De Crea C; Bellantone R
    Langenbecks Arch Surg; 2012 Feb; 397(2):201-7. PubMed ID: 22069043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis.
    Tang Y; Liu Z; Zou Z; Liang J; Lu Y; Zhu Y
    Biomed Res Int; 2018; 2018():9362108. PubMed ID: 29967789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Actual 10-year survivors following resection of adrenocortical carcinoma.
    Tran TB; Postlewait LM; Maithel SK; Prescott JD; Wang TS; Glenn J; Phay JE; Keplinger K; Fields RC; Jin LX; Weber SM; Salem A; Sicklick JK; Gad S; Yopp AC; Mansour JC; Duh QY; Seiser N; Solorzano CC; Kiernan CM; Votanopoulos KI; Levine EA; Hatzaras I; Shenoy R; Pawlik TM; Norton JA; Poultsides GA
    J Surg Oncol; 2016 Dec; 114(8):971-976. PubMed ID: 27633419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Score Predicting Long-Term Survival after Repeat Resection for Recurrent Adrenocortical Carcinoma.
    Tran TB; Maithel SK; Pawlik TM; Wang TS; Hatzaras I; Phay JE; Fields RC; Weber SM; Sicklick JK; Yopp AC; Duh QY; Solorzano CC; Votanopoulos KI; Poultsides GA
    J Am Coll Surg; 2016 Dec; 223(6):794-803. PubMed ID: 27618748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adrenocortical carcinoma surgery-surgical extent and approach.
    Vanbrugghe C; Lowery AJ; Golffier C; Taieb D; Sebag F
    Langenbecks Arch Surg; 2016 Nov; 401(7):991-997. PubMed ID: 27412357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection.
    Terzolo M; Baudin AE; Ardito A; Kroiss M; Leboulleux S; Daffara F; Perotti P; Feelders RA; deVries JH; Zaggia B; De Francia S; Volante M; Haak HR; Allolio B; Al Ghuzlan A; Fassnacht M; Berruti A
    Eur J Endocrinol; 2013 Sep; 169(3):263-70. PubMed ID: 23704714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.